10/535381 #2

JC06 Rec d PCT/PTO 16 MAY 2005

"Express Mail" mailing label number <u>EL & 32 & 93788 US</u>

Date of Deposit <u>// NULL 2005</u>

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 23313-1450.

DUELN HONAS

Printed Name

Signature

<u>PATENT APPLICATION</u> <u>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</u>

First Applicant: Beight, et al.

For:

NOVEL COMPOUNDS AS

PHARMACEUTICAL AGENTS

Docket No.:

X-16014

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

Tina M. Tucker

Attorney for Applicants Registration No. 47,145

Phone: 317-277-3537

Eli Lilly and Company Patent Division/TMT P.O. Box 6288

Indianapolis, Indiana 46206-6288

FORM PT	O 1449	(modified)	Atty. Docket No. X-16014			Serial No. 1535381			
INFORMA IN AN AP		DISCLOSURE CITATION	First Applicant Beight						
				Filing Date			Group		
U.S. PA	TENT	DOCUMENTS							· · · · · ·
Examiner Initials*	Cite No. 1			Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear	
	AA	US							
	AB	US						· ·	-
	AC	US							
	AD								
FOREIC	SN PA	TENT DOCUMENT	<u>rs</u>					<u> </u>	
Examiner Initials*	Cite No. 1	No. ¹ Country Code ³ -Number ⁴ -		Publication Date MM-DD-YYYY		Patentee or nt of Cited ument	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		T ⁶
	BA	Kind Code5 (if known) WO 02 062794	08/15/2		Glaxo		Figures App	ear	
	BB	WO 02 062787	08/15/2002		Glaxo				
	BC WO 02 066462		08/29/2	08/29/2002				•	
	BD	BD WO 02 094833 1		11/28/2002		and y			
	BE								
		NON P	ATENT	LITERAT	URE DOC	CUMENTS	3		•
Examiner Initials*									T ⁶
	СВ								· · ·
							· · · · · · · · · · · · · · · · · · ·	L	

Examiner

Date Considered Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard S1.3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the senia number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard S1.16 if possible. Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.